Загрузка...
ALK Inhibitors in Non–Small Cell Lung Cancer: Crizotinib and Beyond
The treatment of patients with advanced non–small cell lung cancer (NSCLC) harboring chromosomal rearrangements of anaplastic lymphoma kinase (ALK) has been revolutionized by the development of crizotinib, a small molecule inhibitor of the tyrosine kinases ALK, ROS1, and MET. Resistance to crizotini...
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4215402/ https://ncbi.nlm.nih.gov/pubmed/25322323 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|